Literature DB >> 16944368

[Supportive care and palliation in patients with malignant gliomas].

Stefan Oberndorfer1, Heinz Lahrmann.   

Abstract

The primary aim of supportive care in patients with malignant gliomas is accurate symptom control in order to optimize quality of life. The palliative approach should be considered from the beginning of treatment, due to the intractable and incurable character of the disease. Neurological signs and symptoms have to be investigated clinically, as well as neuroradiologically in order to evaluate treatment response and to provide adequate supportive care.

Entities:  

Mesh:

Year:  2006        PMID: 16944368     DOI: 10.1007/s10354-006-0309-2

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  30 in total

Review 1.  Psychopharmacology in supportive care of cancer: a review for the clinician. III. Antidepressants.

Authors:  A Berney; F Stiefel; C Mazzocato; T Buclin
Journal:  Support Care Cancer       Date:  2000-07       Impact factor: 3.603

2.  Timing of anticoagulant therapy for thromboembolic complications after craniotomy for brain tumors.

Authors:  B K Willis
Journal:  Neurosurgery       Date:  1991-06       Impact factor: 4.654

3.  Frontal glioma presenting as anxiety and obsessions: a case report.

Authors:  G John; V Eapen; G K Shaw
Journal:  Acta Neurol Scand       Date:  1997-09       Impact factor: 3.209

4.  Facets and determinants of quality of life in patients with recurrent high grade glioma.

Authors:  A R Giovagnoli; A Silvani; E Colombo; A Boiardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

5.  P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.

Authors:  Stefan Oberndorfer; Maria Piribauer; Christine Marosi; Heinz Lahrmann; Peter Hitzenberger; Wolfgang Grisold
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

6.  Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells.

Authors:  Pratima Sur; Eric A Sribnick; Sunil J Patel; Swapan K Ray; Naren L Banik
Journal:  Glia       Date:  2005-04-15       Impact factor: 7.452

7.  Psychiatric symptoms associated with brain tumors: a clinical enigma.

Authors:  Despina Moise; Subramoniam Madhusoodanan
Journal:  CNS Spectr       Date:  2006-01       Impact factor: 3.790

8.  O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Authors:  Mirjam Hermisson; Andrea Klumpp; Wolfgang Wick; Jörg Wischhusen; Georg Nagel; Wynand Roos; Bernd Kaina; Michael Weller
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

9.  The incidence and significance of thromboembolic complications in patients with high-grade gliomas.

Authors:  R Cheruku; E Tapazoglou; J Ensley; J A Kish; G D Cummings; M al-Sarraf
Journal:  Cancer       Date:  1991-12-15       Impact factor: 6.860

10.  Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.

Authors:  Arabinda Das; Naren L Banik; Sunil J Patel; Swapan K Ray
Journal:  Mol Cancer       Date:  2004-12-08       Impact factor: 27.401

View more
  1 in total

Review 1.  End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.

Authors:  Tobias Walbert; Muhib Khan
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.